Travere Therapeutics Inc [TVTX] stock is trading at $17.87, down -2.08%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TVTX shares have gain 8.90% over the last week, with a monthly amount glided 18.66%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Guggenheim upgraded its rating to Buy on September 09, 2024, and kept the price target unchanged to $25. On March 27, 2024, downgrade downgraded it’s rating to Neutral. Citigroup upgraded its rating to a Buy and increased its price target to $10 on December 05, 2023. Citigroup initiated its recommendation with a Neutral and recommended $7 as its price target on November 20, 2023. Wells Fargo downgraded its rating to Equal Weight for this stock on September 22, 2023, and downed its price target to $8. In a note dated September 21, 2023, William Blair downgraded an Mkt Perform rating on this stock.
Travere Therapeutics Inc [TVTX] stock has fluctuated between $5.12 and $18.82 over the past year. Currently, Wall Street analysts expect the stock to reach $21.5 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $17.87 at the most recent close of the market. An investor can expect a potential return of 20.31% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 177.64M for the trailing twelve months, which represents a drop of -9.35%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -2.13%, Pretax Profit Margin comes in at -2.16%, and Net Profit Margin reading is -0.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -1.02 and Total Capital is -0.88. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 25.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.50 points at the first support level, and at 17.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.29, and for the 2nd resistance point, it is at 18.71.
Ratios To Look Out For
For context, Travere Therapeutics Inc’s Current Ratio is 3.04. In addition, the Quick Ratio stands at 2.99 and the Cash Ratio stands at 0.27. Considering the valuation of this stock, the price to sales ratio is 7.69, the price to book ratio is 90.20.
Transactions by insiders
Recent insider trading involved LYONS GARY A, Director, that happened on Oct 04 ’24 when 40000.0 shares were sold. Officer, GARY A LYONS completed a deal on Oct 04 ’24 to buy 40000.0 shares. Meanwhile, Director Meckler Jeffrey A sold 40000.0 shares on Sep 30 ’24.
